Clinical outcomes of retreatment with daratumumab-based regimens in anti-CD38 refractory multiple myeloma.

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Real-world comparison of daratumumab-based regimens in relapsed/refractory multiple myeloma using health record data2024 · 6 citations
2. 2Final analysis of daratumumab, carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.2026
3. 3Rapid reduction of free light chains and improvement in renal outcomes in patients with newly diagnosed multiple myeloma admitted with acute kidney injury with daratumumab-based therapy and without plasmapheresis.2024 · 2 citations
4. 4Phase 1b study of cyclophosphamide, pomalidomide, dexamethasone, and daratumumab (CPD-DARA) in relapsed/refractory multiple myeloma: Safety and efficacy in a heavily pretreated population2025
5. 5Treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with multiple myeloma: longer follow-up of the real-world MMY4032 study2026